Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Naishadham

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The American Journal of Gastroenterology|June 13, 2012
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis CChihiro Morishima, Mitchell L Shiffman, Jules L Dienstag, et al.
Gastroenterology|March 10, 2010
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis CRobert J Fontana, Arun J Sanyal, Marc G Ghany, et al.
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Hepatology (Baltimore, Md.)|May 13, 2009
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trialTania Mara Welzel, Timothy R Morgan, Herbert L Bonkovsky, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The American Journal of Gastroenterology|June 13, 2012
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis CChihiro Morishima, Mitchell L Shiffman, Jules L Dienstag, et al.
Gastroenterology|March 10, 2010
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis CRobert J Fontana, Arun J Sanyal, Marc G Ghany, et al.
Gastroenterology|September 15, 2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trialMitchell L Shiffman, Chihiro Morishima, Jules L Dienstag, et al.
Hepatology (Baltimore, Md.)|November 30, 2006
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialGregory T Everson, John C Hoefs, Leonard B Seeff, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Hepatology (Baltimore, Md.)|May 13, 2009
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trialTania Mara Welzel, Timothy R Morgan, Herbert L Bonkovsky, et al.
Pageof 3